
Franciszek K GÅ,Ã³wka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5559664/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Metabolic Characteristics of Hashimoto's Thyroiditis Patients and the Role of Microelements and Diet in the Disease Management—An Overview. International Journal of Molecular Sciences, 2022, 23, 6580.	4.1	26
2	Seasonal pattern of vitamin D hydroxyl metabolite concentrations and their association with cardiac medications – an observational study. Journal of King Saud University - Science, 2022, , 102187.	3.5	1
3	Vitamin D Metabolism Gene Polymorphisms and Their Associated Disorders: A Literature Review. Current Drug Metabolism, 2022, 23, 630-651.	1.2	2
4	Serum sCD25 Protein as a Predictor of Lack of Long-Term Benefits from Immunotherapy in Non-Small Cell Lung Cancer: A Pilot Study. Cancers, 2021, 13, 3702.	3.7	4
5	Pharmacokinetic Drug–Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients. International Journal of Molecular Sciences, 2021, 22, 9582.	4.1	26
6	Vitamin D Receptor Gene Polymorphism and Vitamin D Status in Population of Patients with Cardiovascular Disease—A Preliminary Study. Nutrients, 2021, 13, 3117.	4.1	17
7	HPLC Analysis of the Urinary lodine Concentration in Pregnant Women. Molecules, 2021, 26, 6797.	3.8	5
8	The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles. Pharmaceutics, 2021, 13, 1961.	4.5	20
9	Serum endocan concentration and its correlation with severity of hypertensive disorders in pregnancy. Journal of Maternal-Fetal and Neonatal Medicine, 2020, 33, 2313-2319.	1.5	11
10	Determination of total and free voriconazole in human plasma: Application to pharmacokinetic study and therapeutic monitoring. Journal of Pharmaceutical and Biomedical Analysis, 2020, 178, 112952.	2.8	11
11	Measurement of plasma 25-hydroxyvitamin D2, 25-hydroxyvitamin D3 and 3-epi-25-hydroxyvitamin D3 in population of patients with cardiovascular disease by UPLC-MS/MS method. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1159, 122350.	2.3	17
12	New Methods Used in Pharmacokinetics and Therapeutic Monitoring of the First and Newer Generations of Antiepileptic Drugs (AEDs). Molecules, 2020, 25, 5083.	3.8	23
13	Population pharmacokinetic approach for evaluation of treosulfan and its active monoepoxide disposition in plasma and brain on the basis of a rat model. Pharmacological Reports, 2020, 72, 1297-1309.	3.3	0
14	Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats. Pharmaceutics, 2020, 12, 600.	4.5	14
15	Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin. European Journal of Clinical Pharmacology, 2020, 76, 419-430.	1.9	4
16	High-performance liquid chromatography methods for the analysis of endogenous cortisol and cortisone in human urine: comparison of mass spectrometry and fluorescence detection. Annals of Clinical Biochemistry, 2019, 56, 82-89.	1.6	5
17	Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. Biomedicine and Pharmacotherapy, 2019, 116, 108991.	5.6	5
18	Kinetics of <i>in Vitro</i> Guanine- <i>N</i> 7-Alkylation in Calf Thymus DNA by (2 <i>S</i> ,3 <i>S</i>)-1,2-Epoxybutane-3,4-diol 4-methanesulfonate and (2 <i>S</i> ,3 <i>S</i>)-1,2:3,4-Diepoxybutane: Revision of the Mechanism of DNA Cross-Linking by the Prodrug Treosulfan. Molecular Pharmaceutics, 2019, 16, 2708-2718.	4.6	6

#	Article	IF	CITATIONS
19	In Vitro Study of the Enzymatic and Nonenzymatic Conjugation of Treosulfan with Glutathione. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 653-657.	1.6	3
20	Liquid chromatography–tandem mass spectrometry method for simultaneous determination of three N-7-guanine adducts of the active epoxides of prodrug treosulfan in DNA in vitro. Talanta, 2019, 198, 464-471.	5.5	1
21	Cortisol metabolism in pregnancies with small for gestational age neonates. Scientific Reports, 2019, 9, 17890.	3.3	6
22	Development of an LC-MS/MS method for simultaneous determination of ticagrelor and its active metabolite during concomitant treatment with atorvastatin. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1105, 113-119.	2.3	13
23	Bioavailability of mesalazine from two coated formulation tablets. Acta Poloniae Pharmaceutica, 2019, 76, 67-73.	0.1	1
24	Clinical bioanalysis of treosulfan and its epoxides: The importance of collected blood processing for valid pharmacokinetic results. Journal of Pharmaceutical and Biomedical Analysis, 2018, 153, 199-203.	2.8	1
25	Increased cortisol metabolism in women with pregnancy-related hypertension. Endocrine, 2018, 61, 125-133.	2.3	23
26	Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation. European Journal of Clinical Pharmacology, 2018, 74, 79-89.	1.9	15
27	Ticagrelor in modern cardiology - an up-to-date review of most important aspects of ticagrelor pharmacotherapy. Expert Opinion on Pharmacotherapy, 2018, 19, 103-112.	1.8	25
28	Relationship between exposure to treosulfan and its monoepoxytransformer – An insight from population pharmacokinetic study in pediatric patients before hematopoietic stem cell transplantation. European Journal of Pharmaceutical Sciences, 2018, 120, 1-9.	4.0	5
29	In Vivo Red Blood Cells/Plasma Partition Coefficient of Treosulfan and Its Active Monoepoxide in Rats. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 565-571.	1.6	7
30	Treosulfan Pharmacokinetics and its Variability in Pediatric and Adult Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation: Current State of the Art, In-Depth Analysis, and Perspectives. Clinical Pharmacokinetics, 2018, 57, 1255-1265.	3.5	16
31	Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins. Drugs, 2018, 78, 1105-1112.	10.9	30
32	N-7-Guanine Adduct of the Active Monoepoxide of Prodrug Treosulfan: First Synthesis, Characterization, and Decomposition Profile Under Physiological Conditions. Journal of Pharmaceutical Sciences, 2018, 107, 2927-2937.	3.3	4
33	Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 99-107.	1.6	21
34	Kinetic and Mechanistic Study of the pH-Dependent Activation (Epoxidation) of Prodrug Treosulfan Including the Reaction Inhibition in a Borate Buffer. Journal of Pharmaceutical Sciences, 2017, 106, 1917-1922.	3.3	15
35	Development of a Limited Sampling Strategy for the Estimation of Exposure to High-Dose Etoposide After Intravenous Infusion in Pediatric Patients. Therapeutic Drug Monitoring, 2017, 39, 138-144.	2.0	2
36	Determination of prodrug treosulfan and its biologically active monoepoxide in rat plasma, liver, lungs, kidneys, muscle, and brain by HPLC–ESI–MS/MS method. Journal of Pharmaceutical and Biomedical Analysis, 2017, 140, 122-129.	2.8	8

#	Article	IF	CITATIONS
37	Detailed analysis of cortisol, cortisone and their tetrahydro- and allo-tetrahydrometabolites in human urine by LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2017, 140, 174-181.	2.8	16
38	Determinants of high on-treatment platelet reactivity and agreement between VerifyNow and Multiplate assays. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 190-198.	1.2	10
39	Disposition of treosulfan and its active monoepoxide in a bone marrow, liver, lungs, brain, and muscle: Studies in a rat model with clinical relevance. European Journal of Pharmaceutical Sciences, 2017, 109, 616-623.	4.0	10
40	Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite. European Journal of Clinical Pharmacology, 2017, 73, 1623-1632.	1.9	21
41	HSD11B2,RUNX3, and LINE-1 Methylation in Placental DNA of Hypertensive Disorders of Pregnancy Patients. Reproductive Sciences, 2017, 24, 1520-1531.	2.5	20
42	Effect of Temperature on the Kinetics of the Activation of Treosulfan and Hydrolytic Decomposition of Its Active Epoxy Derivatives. Journal of Pharmaceutical Sciences, 2017, 106, 3156-3160.	3.3	7
43	Variants of HSD11B2 gene in hypertensive disorders of pregnancy. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 1360-1365.	1.5	2
44	11 <i>β</i> -Hydroxysteroid Dehydrogenase 2 in Preeclampsia. International Journal of Endocrinology, 2016, 2016, 1-9.	1.5	10
45	Formation Rate–Limited Pharmacokinetics of Biologically Active Epoxy Transformers of Prodrug Treosulfan. Journal of Pharmaceutical Sciences, 2016, 105, 1790-1797.	3.3	11
46	Ocular disposition of treosulfan and its active epoxy-transformers following intravenous administration in rabbits. Drug Metabolism and Pharmacokinetics, 2016, 31, 356-362.	2.2	4
47	Glucocorticoid Metabolism in Hypertensive Disorders of Pregnancy: Analysis of Plasma and Urinary Cortisol and Cortisone. PLoS ONE, 2015, 10, e0144343.	2.5	22
48	Activation of Prodrug Treosulfan at pH 7.4 and 37°C Accompanied by Hydrolysis of Its Active Epoxides: Kinetic Studies with Clinical Relevance. Journal of Pharmaceutical Sciences, 2015, 104, 4433-4442.	3.3	20
49	Pharmacokinetics of treosulfan and its active monoepoxide in pediatric patients after intravenous infusion of high-dose treosulfan prior to HSCT. European Journal of Pharmaceutical Sciences, 2015, 68, 87-93.	4.0	27
50	Penetration of Treosulfan and its Active Monoepoxide Transformation Product into Central Nervous System of Juvenile and Young Adult Rats. Drug Metabolism and Disposition, 2015, 43, 1946-1954.	3.3	10
51	Bupivacaine administered intrathecally versus rectally in the management of intractable rectal cancer pain in palliative care. OncoTargets and Therapy, 2014, 7, 1541.	2.0	6
52	The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Journal of Clinical Pharmacology, 2014, 54, 874-880.	2.0	21
53	Clinical Pharmacokinetics of Clopidogrel and Its Metabolites in Patients with Cardiovascular Diseases. Clinical Pharmacokinetics, 2014, 53, 155-164.	3.5	80
54	HPCE AND HPLC METHODS FOR DETERMINATION OF CLOPIDOGREL AND ITS CARBOXYLIC ACID METABOLITE IN BIOLOGICAL SAMPLES: A COMPARATIVE ANALYSIS. Journal of Liquid Chromatography and Related Technologies, 2014, 37, 620-633.	1.0	3

#	Article	IF	CITATIONS
55	Rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of protein-free pro-drug treosulfan and its biologically active monoepoxy-transformer in plasma and brain tissue. Talanta, 2014, 127, 123-132.	5.5	11
56	Direct high-performance liquid chromatography method with refractometric detection designed for stability studies of treosulfan and its biologically active epoxy-transformers. Journal of Pharmaceutical and Biomedical Analysis, 2013, 72, 145-149.	2.8	12
57	Determination of partition coefficients n-octanol/water for treosulfan and its epoxy-transformers: An example of a negative correlation between lipophilicity of unionized compounds and their retention in reversed-phase chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2013. 923-924. 92-97.	2.3	16
58	Lumbar paravertebral blockade as intractable pain management method in palliative care. OncoTargets and Therapy, 2013, 6, 1187.	2.0	1
59	HPLC–MS/MS method for the simultaneous determination of clopidogrel, its carboxylic acid metabolite and derivatized isomers of thiol metabolite in clinical samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 911, 105-112.	2.3	47
60	Genetic and non-genetic factors affecting the response to clopidogrel therapy. Expert Opinion on Pharmacotherapy, 2012, 13, 663-683.	1.8	38
61	HPLC method for determination of biologically active epoxy-transformers of treosulfan in human plasma: Pharmacokinetic application. Journal of Pharmaceutical and Biomedical Analysis, 2012, 62, 105-113.	2.8	21
62	Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis. European Journal of Drug Metabolism and Pharmacokinetics, 2011, 36, 167-173.	1.6	9
63	HPLC method for determination of fluorescence derivatives of cortisol, cortisone and their tetrahydro- and allo-tetrahydro-metabolites in biological fluids. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 283-289.	2.3	19
64	Capillary Zone Electrophoresis method for determination of (+)-S clopidogrel carboxylic acid metabolite in human plasma and urine designed for biopharmaceutic studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 1013-1018.	2.3	13
65	High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation. Expert Opinion on Investigational Drugs, 2010, 19, 1275-1295.	4.1	27
66	Modulatory effect of chiral nonsteroidal antiâ€inflammatory drugs on apoptosis of human neutrophils. Chirality, 2008, 20, 159-165.	2.6	9
67	CE Determination of Ketoprofen Enantiomers in Clinical Samples of Plasma, Synovial Fluid and Urine. Chromatographia, 2008, 67, 97-105.	1.3	7
68	Enantioselective CE method for pharmacokinetic studies on ibuprofen and its chiral metabolites with reference to genetic polymorphism. Electrophoresis, 2007, 28, 2726-2737.	2.4	29
69	Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2007. 850. 569-574.	2.3	15
70	Determination of roxithromycin in human plasma by HPLC with fluorescence and UV absorbance detection: Application to a pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 852, 669-673.	2.3	18
71	Reply to Comment on a€œDetermination of treosultan in plasma and urine by HPLC with retractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation―by G. Hempel and J. Boos [J. Chromatogr. B 853 (2007) 369–370]. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences,	2.3	0
72	RP-HPLC method with fluorescence detection for determination of small quantities of triamcinolone in plasma in presence of endogenous steroids after derivatization with 9-anthroyl nitrile; pharmacokinetic studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 839, 54-61.	2.3	16

Franciszek K GÅ,Ã³wka

#	Article	IF	CITATIONS
73	High performance capillary electrophoresis method for determination of ibuprofen enantiomers in human serum and urine. Analytica Chimica Acta, 2005, 540, 95-102.	5.4	41
74	Resolution of indobufen enantiomers by capillary zone electrophoresis Pharmacokinetic studies of human serum. Journal of Chromatography A, 2004, 1032, 219-225.	3.7	15
75	High performance capillary electrophoresis for determination of the enantiomers of 2-arylpropionic acid derivatives in human serum. Journal of Pharmaceutical and Biomedical Analysis, 2004, 35, 807-816.	2.8	26
76	Protein binding of indobufen enantiomers: Pharmacokinetics of free fraction?studies after single or multiple doses of rac-indobufen. Chirality, 2002, 14, 736-741.	2.6	6
77	Determination of ketoprofen enantiomers in human serum by capillary zone electrophoresis: man pharmacokinetic studies after administration of rac-ketoprofen tablets. Journal of Pharmaceutical and Biomedical Analysis, 2002, 30, 1035-1045.	2.8	18
78	Stereoselective pharmacokinetics of indobufen from tablets and intramuscular injections in man. , 2000, 12, 38-42.		10
79	LC procedure with SPE for quantification of indobufen enantiomers: pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 2000, 22, 93-100.	2.8	11